SIK3

Across TCGA pan-cancer cohorts, SIK3 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SIK3 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher SIK3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SIK3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and COAD show a favorable association.

SCLC, STAD, and BLCA are the cancer types where SIK3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.068	0.716	<.001	36	view →
STAD	OS	Median	All	0.180	0.672	<.001	18	view →
BLCA	OS	Median	All	0.434	0.723	.023	12	view →
HNSC	DFS	Median	All	1.000	0.313	.022	7	view →
KIRC	OS	Median	All	0.181	0.655	.046	6	view →
SKCM	OS	Median	All	0.210	0.780	.006	4	view →
COAD	DFS	Median	All	1.000	0.461	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SIK3–SCLC (OS)

Open the SCLC breakdown →